Cardiac mapping device market projected to reach $2.75 billion by 2032

The global market for cardiac mapping devices is projected to grow from $1,480 million in 2025 to $2,752 million by 2032, representing a compound annual growth rate (CAGR) of 9.40%, according to a report by LP Information Co., Ltd.

Growth is being driven by the expansion of atrial fibrillation ablation procedures and the integration of Pulsed Field Ablation (PFA) technologies. Key market players include Biosense Webster (under J&J MedTech), Abbott, Medtronic (Affera), Boston Scientific, and MicroPort EP.

Opportunities for the industry include AI annotation, ultrasound fusion, and remote assistance. However, the sector faces challenges such as high equipment costs, the need for specialized training, and cybersecurity concerns. The market is segmented by signal collection channels, with high-density systems (over 128 channels) catering to advanced arrhythmia programs and PFA integration.